Research programme: cannabinoid receptor agonists - Cara

Drug Profile

Research programme: cannabinoid receptor agonists - Cara

Alternative Names: CR08; CR701; CR859

Latest Information Update: 24 Jan 2011

Price : $50

At a glance

  • Originator Cara Therapeutics
  • Class
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory pain; Neuropathic pain

Most Recent Events

  • 24 Jan 2011 Preclinical development is ongoing in USA
  • 26 Feb 2007 Preclinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top